(Alliance News) - GSK PLC on Thursday said its Blenrep drug has shown overall survival benefits in patients with relapsed or refractory multiple myeloma, the third most common type of blood cancer.
Third quarter results highlight strong operational performance across key value drivers: YUPELRI® (revefenacin) net sales of $62.2 million, recognized by Viatris ...
The cough and cold relief drugs brand from Procter and Gamble topped the list of Rx and OTC pharma brands by impressions ...
The KSE-100 index of Pakistan Stock Exchange (PSX) lost on Tuesday more than 400 points, weighed down by institutional profit ...
The FTSE 100 index slumped 99.42 points, 1.2%, at 8,025.77. The FTSE 250 closed down 295.73 points, 1.4%, at 20,427.80. The AIM All-Share fell 7.07 points, 1.0%, at 730.86.
In a report released today, Peter Welford from Jefferies downgraded GlaxoSmithKline (GSK – Research Report) to a Hold, with a price ...
Hosted on MSN2d
GSK lowered to hold by Jefferies, valuation disconnect citedJefferies lowered GSK (NYSE:GSK) to hold, citing a valuation disconnect between fundamentals and price. Jefferies said it ...
GSK Plc agreed on a partnership deal worth as much as $650 million with US biotech Vesalius Therapeutics to help advance drug ...
TipRanks on MSN2d
GSK downgraded to Hold from Buy at JefferiesJefferies analyst Peter Welford downgraded GSK (GSK) to Hold from Buy with a price target of $39.50, down from $53. The firm ...
23andMe's big push into drug development, announced with great fanfare almost a decade ago, has ended with a whimper and ...
Detailed price information for 23Andme Holding Co. (ME-Q) from The Globe and Mail including charting and trades.
Topline Securities Ltd said the index was lifted by positive contributions from Oil and Gas Development Company Ltd, Pakistan ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback